Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer.
Saved in:
| Title: | Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer. |
|---|---|
| Authors: | Gerber DE; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas., Infante JR; Janssen Pharmaceuticals, Inc., Raritan, New Jersey., Gordon MS; HonorHealth Research Institute, Scottsdale, Arizona., Goldberg SB; Yale School of Medicine, New Haven, Connecticut., Martín M; Instituto De Investigacion Sanitaria Gregorio Marañon, Ciberonc, Universidad Complutense, Madrid, Spain., Felip E; Vall d'Hebron Institute of Oncology, Barcelona, Spain., Martinez Garcia M; Hospital del Mar, Barcelona, Spain., Schiller JH; Inova Fairfax Hospital, Annandale, Virginia., Spigel DR; Sarah Cannon Research Institute, Nashville, Tennessee., Cordova J; Genentech, Inc., South San Francisco, California., Westcott V; Genentech, Inc., South San Francisco, California., Wang Y; Genentech, Inc., South San Francisco, California., Shames DS; Genentech, Inc., South San Francisco, California., Choi Y; Genentech, Inc., South San Francisco, California., Kahn R; Genentech, Inc., South San Francisco, California., Dere RC; Genentech, Inc., South San Francisco, California., Samineni D; Genentech, Inc., South San Francisco, California., Xu J; Genentech, Inc., South San Francisco, California., Lin K; Genentech, Inc., South San Francisco, California., Wood K; Genentech, Inc., South San Francisco, California., Royer-Joo S; Genentech, Inc., South San Francisco, California., Lemahieu V; Genentech, Inc., South San Francisco, California., Schuth E; Genentech, Inc., South San Francisco, California., Vaze A; Genentech, Inc., South San Francisco, California., Maslyar D; Genentech, Inc., South San Francisco, California., Humke EW; Genentech, Inc., South San Francisco, California., Burris HA 3rd; Sarah Cannon Research Institute, Nashville, Tennessee. howard.burris@SarahCannon.com. |
| Source: | Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2020 Jan 15; Vol. 26 (2), pp. 364-372. Date of Electronic Publication: 2019 Sep 20. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Multicenter Study |
| Journal Info: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
